

THE EVOLVING LANDSCAPE OF HEMOPHILIA A TREATMENTS: GAINS VS. UNMET NEEDS

Boey Cheng¹, Felix Hey², Aine Kyle³

¹Ipsos, Kuala Lumpur, Malaysia, ²Ipsos, Nuremberg, ³Ipsos, London, United Kingdom

INTRODUCTION

In the past decade, there have been significant advancements in the treatment of Hemophilia A; however, certain challenges persist.

OBJECTIVES

The aim of this study is to assess physicians' association of standard half-life products and advanced therapies for hemophilia A with key metrics and identify any unmet needs.

METHODS

The Ipsos Hemophilia Therapy Monitor is a multi-country online survey conducted among 176 physicians specialized in treating patients with hemophilia A in France (n=30), Germany (n=40), Italy (n=40), Spain (n=40) and the United Kingdom (n=26). Data was collected between November 2022 and February 2023.

CONCLUSIONS

In this study, sampled physicians were more likely to associate advanced therapies with convenience, patient compliance and satisfaction, compared to standard half-life treatments, while less disparity was seen when associating the two groups with optimizing trough levels and long-term safety. This study underscores the progress made and the challenges that lie ahead in hemophilia A treatment. Further investigation using comparator cohort is warranted.



According to our data, physicians note improved convenience and patient compliance with advanced hemophilia A therapies, compared to standard half-life products



SCAN TO DOWNLOAD THE POSTER & ABSTRACT


CONTACT US: TherapyMonitors@ipsos.com

E-POSTER NUMBER: P2256

EHA 2024, MADRID, 13th-16th OF JUNE

RESULTS

Figure 1: Sampled physician cited association of hemophilia A treatments with key metrics



Source: Ipsos Hemophilia Therapy Monitor (Nov 2022 – Feb 2023, 176 hematologists and hem-oncologists across FR, DE, IT, ES & UK treating hemophilia patients, data collected online. Participating physicians were primary treaters and saw a minimum number of patients per wave. Data are © Ipsos 2024, all rights reserved. Advanced therapies include rFVIII-Fc, rFVIII-single chain and FVIII-mimetic. ** indicates statistical difference at 99% confidence level